Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

  • STATUS
    Recruiting
  • days left to enroll
    88
  • participants needed
    324
  • sponsor
    Bial - Portela C S.A.
Send
Updated on 4 August 2021
See if I qualify

Summary

Opicapone (OPC) is a third generation catechol O methyltransferase (COMT) inhibitor (COMTi) developed by BIAL-Portela & C, S.A. It is approved as adjunctive therapy to preparations of L-DOPA/DDCI in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations. Carbidopa and benserazide are both DDCIs used in association with L DOPA. When OPC is co administered with L DOPA/DDCI, peripheral COMT is inhibited and thus L DOPA plasma levels increase, increasing L DOPA bioavailability. The purpose of this Phase III study is to explore the potential of OPC to enhance the clinical benefit of L-DOPA in L DOPA treated patients in the early stages of Parkinson's Disease (PD) (patients without end-of-dose motor fluctuations, 'non fluctuators').

Description

This is a Phase III study to evaluate the efficacy and safety of OPC in subjects with early idiopathic PD receiving treatment with L DOPA plus a DDCI, and who are without signs of any motor complication (consisting of fluctuations in the motor response and/or involuntary movements or dyskinesias).

After a screening period of up to 4 weeks, eligible subjects will be randomized into 1 of 2 treatment arms (OPC 50 mg, or placebo) in a 1:1 ratio, and enter a 24-week placebo-controlled, parallel-group, double blind period.

At the end of the double-blind period, subjects may enter an additional 1-year, open-label period, at the discretion of both the Investigator and subject, in which all subjects will be treated with OPC 50 mg.

A Post-study Visit (PSV) will be performed approximately 2 weeks after the End of Study Visit (EOS) or Early Discontinuation Visit (EDV).

Study treatment will be administered in combination with existing treatment of L-DOPA/DDCI.

Details
Condition Parkinson
Treatment Placebo, Opicapone 50 mg
Clinical Study IdentifierNCT04978597
SponsorBial - Portela C S.A.
Last Modified on4 August 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Capable of giving signed informed consent
Subjects must be 30 to 80 years of age, inclusive, at the time of signing the ICF
Diagnosed with idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria within the previous 5 years
Disease severity Stages 1 to 2.5 (according to the modified Hoehn & Yahr staging)
Signs of treatable motor disability for a minimum of 4 weeks before screening, with minimum threshold with MDS-UPDRS Part III score of 20 at both screening and Visit 2, despite stable anti-PD therapy (based on the investigator's judgment)
Receiving treatment with L-DOPA/DDCI (either controlled-release, immediate-release or combined controlled immediate-release) for at least 1 year, and at a stable regimen for at least 4 weeks prior to Visit 2 at a daily dose in the range 300 to 500 mg, 3 to 4 times a day
Naive to COMT inhibitors (including OPC)
Male or female
A male subject must agree to use contraception during the treatment period and
until the PSV, and refrain from donating sperm during this period
A female subject is eligible to participate if she is not pregnant , not
breastfeeding, and at least 1 of the following conditions applies: i) Not a
woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow
the contraceptive guidance during the treatment period and until the PSV
\. Results of the screening laboratory tests are considered clinically
acceptable by the Investigator (ie, not clinically relevant for the well-being
of the subject or for the purpose of the study)

Exclusion Criteria

Non-idiopathic PD (for example, atypical parkinsonism, secondary [acquired or symptomatic] parkinsonism, Parkinson-plus syndrome)
Signs of motor complications with a total score of MDS-UPDRS Part IV A+B+C greater than '0' (zero)
Treatment with prohibited medication: COMT inhibitors (eg, entacapone, tolcapone), antiemetics with antidopaminergic action (except domperidone) or Duopa (carbidopa/levodopa intestinal gel) within the 4 weeks before screening
Concomitant use of monoamine oxidase (MAO-A and MAO-B) inhibitors (eg, phenelzine, tranylcypromine and moclobemide) other than those for the treatment of PD
Previous or planned (during the entire study duration) deep brain stimulation
Previous stereotactic surgery (eg, pallidotomy, thalamotomy) for PD or with planned stereotactic surgery during the study period
Any investigational medicinal product within the 3 months (or within 5 half-lives, whichever is longer) before screening
Any medical condition that might place the subject at increased risk or interfere with study assessments
Past (within the past year) or present history of suicidal ideation or suicide attempts, as determined by a positive response ('Yes') to either Question 4 or Question 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) (Screening questions)
Current or previous (within the past year) diagnosis of psychosis, severe major depression, or other psychiatric disorders that, based on the Investigator's judgment, might place the subject at increased risk or interfere with assessments
A clinically relevant electrocardiogram (ECG) abnormality (relevance should be assessed by a cardiologist if needed)
Current evidence of unstable cardiovascular disease, including but not limited to uncontrolled hypertension, myocardial infarction with important systolic or diastolic dysfunction, unstable angina, congestive heart failure (New York Heart Association Class III), and significant cardiac arrhythmia (Mobitz II 2nd or 3rd degree AV block or any other arrhythmia causing hemodynamic repercussions as symptomatic bradycardia or syncope)
Prior renal transplant or current renal dialysis
Pheochromocytoma, paraganglioma or other catecholamine secretive neoplasm
Known hypersensitivity to any ingredients of the study treatment
History of neuroleptic malignant syndrome (NMS) or NMS-like syndromes, or non-traumatic rhabdomyolysis
Malignancy within the past 5 years (eg, melanoma, prostate cancer), excluding cutaneous basal or squamous cell cancer resolved by excision
Unstable active narrow-angle or unstable wide-angle glaucoma
History of or current evidence of any relevant disease in the context of this study, ie, with respect to the safety of the subject or related to the study conditions, eg, which may influence the absorption or metabolism (such as a relevant liver disease) of the study treatment
Any abnormality in the liver enzymes (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]) >2 times the upper limit of the normal range, in the screening laboratory tests results
Plasma sodium less than 130 mmol/L, white blood cell count less than 3000 cells/mm3, or any other relevant clinical laboratory abnormality that, in the Investigator's opinion, may compromise the subject's safety
Positive SARS-CoV-2 test at screening
Evidence of an ICD (one or more positive modules on the mMIDI)
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note